Open AccessHigh expression of TRF 2, SOX 10, and CD 10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness
Author(s) -
Long Elodie,
Ilie Marius,
Bence Coraline,
Butori Catherine,
Selva Eric,
Lalvée Salomé,
Bonnetaud Christelle,
Poissonnet Gilles,
Lacour JeanPhilippe,
Bahadoran Philippe,
Brest Patrick,
Gilson Eric,
Ballotti Robert,
Hofman Véronique,
Hofman Paul
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.661
Subject(s) - circulating tumor cell , medicine , melanoma , metastatic melanoma , phenotype , antibody , homogeneous , matrix metalloproteinase , cancer research , metastasis , pathology , immunology , biology , cancer , gene , physics , thermodynamics , biochemistry
Circulating tumors cells ( CTC s) can be detected in the blood of metastatic melanoma patients ( MMP s) both as isolated circulating tumor cells ( iCTC s) and circulating tumor microemboli ( CTM s), but their clinical significance remains unknown. The aim of this work was to evaluate the prognostic impact in metastatic cutaneous melanoma of CTM s and iCTC s identified by a cytomorphological approach using the isolation by size of tumor cell ( ISET ) method. We characterized the phenotype of CTC s using anti‐ PS 100, anti‐ SOX 10, anti‐ CD 10, and anti‐ TRF 2 antibodies. 128 MMP s and 37 control healthy individuals with benign nevi were included in this study. Results were compared to the follow‐up of patients. 109/128 (85%) MMP s showed CTC s, 44/128 (34%) with 2 to 6 CTM s and 65/128 (51%) with 4 to 9 iCTC s. PS 100 expression was homogeneous in iCTC s and heterogeneous in CTM s. SOX 10, CD 10, and TRF 2 were mainly expressed in CTM s. None of the control subjects demonstrated circulating malignant tumor cells. Overall survival was significantly decreased in patients with CTM s, independently of the therapeutic strategies. In conclusion, the presence of CTM s is an independent predictor of shorter survival from the time of diagnosis of MMPs.